Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

58 results
Display

Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer

Hyung J, Cho EJ, Kim J, Kim JH, Kim JE, Hong YS, Kim TW, Sung CO, Kim SY

Purpose Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability‒high (MSI-H) colorectal cancer (CRC), and factors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers

Noh JJ, Kim MK, Choi MC, Lee JW, Park H, Jung SG, Joo WD, Song SH, Lee C

Purpose This study was to investigate the frequency of mismatch repair deficiency/high microsatellite instability (MMRd/MSI-H) in gynecologic malignancies and the efficacy of immune checkpoint inhibitors (ICIs) in patients with recurrent gynecologic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials

Yin Q, Dai L, Sun R, Ke P, Liu L, Jiang B

Purpose This network meta-analysis (NMA) was conducted to compare the efficacy of immune checkpoint inhibitors in advanced non–small cell lung cancer (NSCLC) patients with liver metastases. Materials and Methods English literature...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates

Kawashima S, Joachim K, Abdelrahim M, Abudayyeh A, Jhaveri KD, Murakami N

Transplant care continues to advance with increasing clinical experience and improvements in immunosuppressive therapy. As the population ages and long-term survival improves, transplant patient care has become more complex due...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent Progress in Immunotherapy for Advanced Gastric Cancer

Sohn BS

Immune checkpoint inhibition has been established as a new treatment option for various types of carcinoma, and many clinical trials are being actively conducted as a treatment for advanced or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer

Shin HS, Choi J, Lee J, Lee SY

Purpose Histone deacetylase inhibitors (HDACis) are epigenetic regulators and used clinically for hematopoietic malignancies. Recently, HDACis have received attention as a factor that modulates the immune system. In this study,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy

Chen Y, Huang H, Liu Y, Wang Z, Wang L, Wang Q, Zhang Y, Wang H

Purpose The purpose of this study was to optimize a peptide (nABP284) that binds to programmed cell death protein 1 (PD-1) by a computer-based protocol in order to increase its affinity....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Kim H, Kwon HJ, Kim ES, Kwon S, Suh KJ, Kim SH, Kim YJ, Lee JS, Chung JH

Purpose Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
TcellInflamedDetector: an R package to distinguish T cell inflamed tumor types from non–T cell inflamed tumor types

Yang SD, Park HS

A major issue in the use of immune checkpoint inhibitors is their lack of efficacy in many patients. Previous studies have reported that the T cell inflamed signature can help...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Drug-Induced Sarcoidosis-Like Reaction in Lung Cancer Patient Treated with Nivolumab and Ipilimumab: A Case Report and Literature Review

Kim SH, Lee SG, Kim JY, Ju HJ, Kim GM, Lee JH

  • KMID: 2527682
  • Korean J Dermatol.
  • 2022 Mar;60(3):182-185.
Immune checkpoint inhibitor (ICI), including programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 inhibitors, has emerged as a pillar in the management of advanced malignancies. A drug-induced sarcoidosis-like...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report

Park MK, Yu SJ

Treatment options for advanced hepatocellular carcinoma (HCC) have been rapidly evolving. Herein, we describe a patient with advanced HCC and portal vein tumor thrombosis (PVTT) who responded decisively to a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors

Inaba H, Kaido Y, Ito S, Hirobata T, Inoue G, Sugita T, Yamamoto Y, Jinnin M, Kimura H, Kobayashi T, Iwama S, Arima H, Matsuoka T

Background: Type 1 diabetes mellitus induced by immune-checkpoint inhibitors (ICI-T1DM) is a rare critical entity. However, the etiology of ICI-T1DM remains unclear. Methods: In order to elucidate risk factors for ICI-T1DM,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors

Kim SH, Park EY, Lee HH, Chung J, Seo HK

Purpose: This study aimed to determine the prognostic roles of several immune-related laboratory parameters in patients with metastatic kidney and bladder cancer treated with immune checkpoint inhibitors (ICIs). Materials and Methods:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy

Bae J, Park K, Kim YM

Cancer is one of the leading causes of death worldwide and the number of cancer patients is expected to continuously increase in the future. Traditional cancer therapies focus on inhibiting...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy

Lee JB, Kim HR, Ha SJ

Targeting immune evasion via immune checkpoint pathways has changed the treatment paradigm in cancer. Since CTLA-4 antibody was first approved in 2011 for treatment of metastatic melanoma, eight immune checkpoint...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports

Baek JH

Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lumbosacral polyradiculoneuropathy associated with combination therapy of nivolumab and ipilimumab

Cho EB, Kim SJ, Yang TW, Jung S, Jeong H, Park KJ

Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising therapeutic options for advanced cancers. While ICIs have improved survival in multiple cancers, their increased use is restricted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors

Yoon E, Kim TY, Mun SK, Cho D

Immune-related adverse events, including immune hemolytic anemia, have been reported in patients treated with immune checkpoint inhibitors. In particular, RBC autoantibodies are important because they can cause hemolytic anemia and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report

Baek DW, Chae YS

Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report

Han JE, Cho HJ, Kim SS, Cheong JY

The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr